• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雾化包裹交联壳聚糖纳米粒的 siRNA 用于肺部给药。

Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery.

机构信息

UCL, School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK.

出版信息

Int J Pharm. 2013 Oct 15;455(1-2):241-7. doi: 10.1016/j.ijpharm.2013.07.024. Epub 2013 Jul 20.

DOI:10.1016/j.ijpharm.2013.07.024
PMID:23876499
Abstract

PURPOSE

To explore the potential of crosslinked chitosan nanoparticles as carriers for delivery of siRNA using a jet nebuliser.

MATERIALS AND METHODS

Nanoparticles encapsulating siRNA were prepared using an ionic crosslinking technique at chitosan to siRNA weight/weight ratios of 10:1, 30:1 and 50:1. Particles were characterised for their size, charge, morphology, pH stability and siRNA encapsulation efficiency. Gel electrophoresis was used to assess the association and stability of siRNA with nanoparticles, including after aerosolisation using a Pari LC Sprint jet nebuliser. The aerosolisation properties of FITC labelled chitosan nanoparticles were investigated using a two-stage impinger. Cell viability was performed with H-292 cells using a WST-1 assay.

RESULTS

Positively charged spherical nanoparticles were produced with mean diameters less than 150 nm, at all chitosan to siRNA ratios. Nanoparticles were non-aggregated at the pH of the airways and showed high siRNA encapsulation efficiency (>96%). Complete binding of siRNA to chitosan nanoparticles was observed when the w/w ratio was 50:1. Nebulisation produced fine particle fractions of 54±11% and 57.3±1.9% for chitosan and chitosan:siRNA (10:1 w/w) nanoparticles respectively. The stability of chitosan-encapsulated siRNA was maintained after nebulisation. Cell viability was high (>85%) at the highest chitosan concentration (83 μg/ml).

CONCLUSION

The results suggest that crosslinked chitosan nanoparticles have potential for siRNA delivery to the lungs using a jet nebuliser.

摘要

目的

探索使用喷射雾化器将交联壳聚糖纳米粒子作为 siRNA 传递载体的潜力。

材料和方法

使用离子交联技术,在壳聚糖与 siRNA 的重量/重量比为 10:1、30:1 和 50:1 的情况下制备包封 siRNA 的纳米粒子。对粒子的粒径、电荷、形态、pH 稳定性和 siRNA 包封效率进行了表征。凝胶电泳用于评估 siRNA 与纳米粒子的结合和稳定性,包括使用 Pari LC Sprint 喷射雾化器进行雾化后。使用两步冲击器研究了 FITC 标记壳聚糖纳米粒子的雾化特性。使用 WST-1 测定法对 H-292 细胞进行细胞活力测定。

结果

在所有壳聚糖与 siRNA 比例下,均产生了平均直径小于 150nm 的带正电荷的球形纳米粒子。纳米粒子在气道 pH 值下未聚集,并显示出高的 siRNA 包封效率(>96%)。当 w/w 比为 50:1 时,观察到 siRNA 与壳聚糖纳米粒子的完全结合。雾化产生了 54±11%和 57.3±1.9%的细颗粒分数,分别为壳聚糖和壳聚糖:siRNA(10:1 w/w)纳米粒子。雾化后壳聚糖包封的 siRNA 稳定性得以维持。细胞活力在最高壳聚糖浓度(83μg/ml)时>85%。

结论

结果表明,交联壳聚糖纳米粒子具有通过喷射雾化器将 siRNA 递送到肺部的潜力。

相似文献

1
Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery.雾化包裹交联壳聚糖纳米粒的 siRNA 用于肺部给药。
Int J Pharm. 2013 Oct 15;455(1-2):241-7. doi: 10.1016/j.ijpharm.2013.07.024. Epub 2013 Jul 20.
2
Development and characterisation of chitosan nanoparticles for siRNA delivery.用于小干扰RNA递送的壳聚糖纳米颗粒的研发与表征
J Control Release. 2006 Oct 10;115(2):216-25. doi: 10.1016/j.jconrel.2006.07.021. Epub 2006 Jul 25.
3
The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing.聚合物性质对壳聚糖/小干扰RNA纳米颗粒制剂及基因沉默的影响。
Biomaterials. 2007 Feb;28(6):1280-8. doi: 10.1016/j.biomaterials.2006.11.004.
4
Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery.用于小干扰RNA递送的壳聚糖/聚古罗糖醛酸纳米颗粒的制备与表征
J Control Release. 2009 Oct 15;139(2):146-52. doi: 10.1016/j.jconrel.2009.06.018. Epub 2009 Jun 28.
5
Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells.超细微壳聚糖纳米粒作为一种靶向神经元细胞的高效核酸传递系统。
Drug Dev Ind Pharm. 2009 Jun;35(6):719-26. doi: 10.1080/03639040802526789.
6
Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.壳聚糖纳米粒用于 siRNA 递送:优化配方以提高稳定性和效率。
J Control Release. 2014 Feb 28;176:54-63. doi: 10.1016/j.jconrel.2013.12.026. Epub 2013 Dec 31.
7
Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers.使用不同交联剂的壳聚糖纳米颗粒对siRNA的稳定性、细胞内递送及释放
PLoS One. 2015 Jun 11;10(6):e0128963. doi: 10.1371/journal.pone.0128963. eCollection 2015.
8
siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing.壳聚糖纳米粒介导的 siRNA 递送:有利于高效基因沉默的分子特性。
J Control Release. 2012 Mar 10;158(2):261-8. doi: 10.1016/j.jconrel.2011.11.012. Epub 2011 Nov 17.
9
Development and characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate nanoparticles.基于壳聚糖-脱氧胆酸钠纳米粒的新型质粒递释系统的构建与特性研究。
Eur J Pharm Sci. 2012 Mar 12;45(4):451-8. doi: 10.1016/j.ejps.2011.09.018. Epub 2011 Oct 1.
10
An inhalable β₂-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung.一种可吸入的β₂-肾上腺素能受体配体导向的胍基化壳聚糖载体,用于将 siRNA 靶向递送至肺部。
J Control Release. 2012 Aug 20;162(1):28-36. doi: 10.1016/j.jconrel.2012.06.005. Epub 2012 Jun 12.

引用本文的文献

1
Chitosan Nanoparticle-Based Drug Delivery Systems: Advances, Challenges, and Future Perspectives.基于壳聚糖纳米颗粒的药物递送系统:进展、挑战与未来展望
Polymers (Basel). 2025 May 23;17(11):1453. doi: 10.3390/polym17111453.
2
Chitosan as a Plurivalent Biopolymer in Nanodelivery Systems.壳聚糖作为纳米递送系统中的多价生物聚合物
Polymers (Basel). 2025 Feb 20;17(5):558. doi: 10.3390/polym17050558.
3
Smart Physicochemical-triggered Chitosan-based Nanogels for siRNA Delivery and Gene Therapy: A Focus on Emerging Strategies and Paradigms for Cancer Therapy.
用于 siRNA 递送和基因治疗的智能物理化学触发的壳聚糖基纳米凝胶:聚焦癌症治疗的新兴策略和范例
Curr Med Chem. 2024 Jun 5. doi: 10.2174/0109298673286052240426044945.
4
Excipients for Novel Inhaled Dosage Forms: An Overview.新型吸入制剂辅料:概述。
AAPS PharmSciTech. 2024 Feb 14;25(2):36. doi: 10.1208/s12249-024-02741-w.
5
Delivery of nucleic acids using nanomaterials.使用纳米材料递送核酸。
Mol Biomed. 2023 Dec 14;4(1):48. doi: 10.1186/s43556-023-00160-0.
6
Rational design of multistage drug delivery vehicles for pulmonary RNA interference therapy.多阶段药物传递载体用于肺部 RNA 干扰治疗的合理设计。
Int J Pharm. 2020 Dec 15;591:119989. doi: 10.1016/j.ijpharm.2020.119989. Epub 2020 Oct 26.
7
In Vitro and In Vivo Assessment of PEGylated PEI for Anti-IL-8/CxCL-1 siRNA Delivery to the Lungs.聚乙二醇化聚乙烯亚胺用于抗IL-8/CxCL-1小干扰RNA肺部递送的体外和体内评估
Nanomaterials (Basel). 2020 Jun 27;10(7):1248. doi: 10.3390/nano10071248.
8
Self-Assembled chitosan/phospholipid nanoparticles: from fundamentals to preparation for advanced drug delivery.自组装壳聚糖/磷脂纳米粒:从基础到先进药物递释系统的制备。
Drug Deliv. 2020 Dec;27(1):200-215. doi: 10.1080/10717544.2020.1716878.
9
Natural Polysaccharides for siRNA Delivery: Nanocarriers Based on Chitosan, Hyaluronic Acid, and Their Derivatives.天然多糖用于 siRNA 递送:基于壳聚糖、透明质酸及其衍生物的纳米载体。
Molecules. 2019 Jul 15;24(14):2570. doi: 10.3390/molecules24142570.
10
Recent Advances in Chitosan-Based Carriers for Gene Delivery.壳聚糖基载体在基因传递中的最新进展。
Mar Drugs. 2019 Jun 25;17(6):381. doi: 10.3390/md17060381.